Structure Activity Relationships of 5-, 6-, and 7-Methyl-Substituted Azepan-3-one Cathepsin K Inhibitors
The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substit...
Saved in:
Published in | Journal of medicinal chemistry Vol. 49; no. 5; pp. 1597 - 1612 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
WASHINGTON
American Chemical Society
09.03.2006
Amer Chemical Soc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K i,app = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K i,app = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere. |
---|---|
AbstractList | The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K i,app = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K i,app = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere. The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K(i,app) = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K(i,app) = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere.The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K(i,app) = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K(i,app) = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere. The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-iiiethyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and stereochemical configuration, methyl-substituted azepanones were identified that had widely varied cathepsin K inhibitory potency as well as pharmacokinetic properties compared to the 4S-parent azepanone analogue, 1 (human cathepsin K, K-i,K-app = 0.16 nM, rat oral bioavailability = 42%, rat in vivo clearance = 49.2 mL/min/kg). Of particular note, the 4S-7-cis-methylazepanone analogue, 10, had a K-i,K-app = 0.041 nM vs human cathepsin K and 89% oral bioavailability and an in vivo clearance rate of 19.5 mL/min/kg in the rat. Hypotheses that rationalize some of the observed characteristics of these closely related analogues have been made using X-ray crystallography and conformational analysis. These examples demonstrate the potential for modulation of pharmacological properties of cathepsin inhibitors by substituting the azepanone core. The high potency for inhibition of cathepsin K coupled with the favorable rat and monkey pharmacokinetic characteristics of compound 10, also known as SB-462795 or relacatib, has made it the subject of considerable in vivo evaluation for safety and efficacy as an inhibitor of excessive bone resorption in rat, monkey, and human studies, which will be reported elsewhere. |
Author | Offen, Priscilla H Lark, Michael W Wang, Bing Veber, Daniel F Marquis, Robert W Nidamarthy, Sirishkumar D Roethke, Theresa J James, Ian E Cheng, H-Y Tomaszek, Thaddeus Lin, Fan Smith, Ward W Ward, Keith W Zhao, Baoguang Head, Martha S Yamashita, Dennis S Smith, Brian R Erhard, Karl F McQueney, Michael Liable-Sands, Louise M Gress, Catherine J Janson, Cheryl A Geng, Xiaoliu Nevins, Neysa Narducci Sarjeant, Amy A Xie, Ren Jeong, Jae U Haltiwanger, R. Curtis Oh, Hye-Ja Gao, Enoch Zembryki, Denise L |
Author_xml | – sequence: 1 givenname: Dennis S surname: Yamashita fullname: Yamashita, Dennis S – sequence: 2 givenname: Robert W surname: Marquis fullname: Marquis, Robert W – sequence: 3 givenname: Ren surname: Xie fullname: Xie, Ren – sequence: 4 givenname: Sirishkumar D surname: Nidamarthy fullname: Nidamarthy, Sirishkumar D – sequence: 5 givenname: Hye-Ja surname: Oh fullname: Oh, Hye-Ja – sequence: 6 givenname: Jae U surname: Jeong fullname: Jeong, Jae U – sequence: 7 givenname: Karl F surname: Erhard fullname: Erhard, Karl F – sequence: 8 givenname: Keith W surname: Ward fullname: Ward, Keith W – sequence: 9 givenname: Theresa J surname: Roethke fullname: Roethke, Theresa J – sequence: 10 givenname: Brian R surname: Smith fullname: Smith, Brian R – sequence: 11 givenname: H-Y surname: Cheng fullname: Cheng, H-Y – sequence: 12 givenname: Xiaoliu surname: Geng fullname: Geng, Xiaoliu – sequence: 13 givenname: Fan surname: Lin fullname: Lin, Fan – sequence: 14 givenname: Priscilla H surname: Offen fullname: Offen, Priscilla H – sequence: 15 givenname: Bing surname: Wang fullname: Wang, Bing – sequence: 16 givenname: Neysa surname: Nevins fullname: Nevins, Neysa – sequence: 17 givenname: Martha S surname: Head fullname: Head, Martha S – sequence: 18 givenname: R. Curtis surname: Haltiwanger fullname: Haltiwanger, R. Curtis – sequence: 19 givenname: Amy A surname: Narducci Sarjeant fullname: Narducci Sarjeant, Amy A – sequence: 20 givenname: Louise M surname: Liable-Sands fullname: Liable-Sands, Louise M – sequence: 21 givenname: Baoguang surname: Zhao fullname: Zhao, Baoguang – sequence: 22 givenname: Ward W surname: Smith fullname: Smith, Ward W – sequence: 23 givenname: Cheryl A surname: Janson fullname: Janson, Cheryl A – sequence: 24 givenname: Enoch surname: Gao fullname: Gao, Enoch – sequence: 25 givenname: Thaddeus surname: Tomaszek fullname: Tomaszek, Thaddeus – sequence: 26 givenname: Michael surname: McQueney fullname: McQueney, Michael – sequence: 27 givenname: Ian E surname: James fullname: James, Ian E – sequence: 28 givenname: Catherine J surname: Gress fullname: Gress, Catherine J – sequence: 29 givenname: Denise L surname: Zembryki fullname: Zembryki, Denise L – sequence: 30 givenname: Michael W surname: Lark fullname: Lark, Michael W – sequence: 31 givenname: Daniel F surname: Veber fullname: Veber, Daniel F |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17595047$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16509577$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkkGP0zAQhS20iO0uHPgDKBdWQmDWdmI7OVYFll2KQLSIo-U4E9UldYLtAOXX49LSldAeOFgeyd8bP72ZM3TiegcIPabkJSWMXq43hJOK8vEemlDOCC5KUpygCSGMYSZYforOQlgTQnLK8gfolIrEcyknaLWIfjRx9JBNTbTfbdxmn6DT0fYurOwQsr7NOH6RiXS0azKJ30NcbTu8GOsQbRwjNNn0Fwza4RwnX9lMxxUMwbrsXXbtVra2sffhIbrf6i7Ao8N9jj6_eb2cvcXzD1fXs-kc66KQETeFJAJaQUTF6rIptDC8bBmQoiWQqkqIipO6rKkRHPKiaspaVCVrtM6ByTI_Rxf7voPvv40QotrYYKDrtIN-DEpISakkLIFPDuBYb6BRg7cb7bfqbzYJeHoAdDC6a712xoZbTvLkpNhxz_fcD6j7NhgLzsARS6GzXBDCi1TR3bfl_9MzG_9MYtaPLibp5V5qfB-Ch1aZw3v02naKErVbB3Vch6R49o_i6P4OFu9ZGyL8PILaf02Z5ZKr5ceFqr7cLK9u5qV6dRuPNkGt-9G7NNY7-v4GuffLhw |
CODEN | JMCMAR |
CitedBy_id | crossref_primary_10_1016_j_bmcl_2008_12_053 crossref_primary_10_3390_molecules22111871 crossref_primary_10_1021_bi8007627 crossref_primary_10_1096_fj_06_7924com crossref_primary_10_1007_s00223_009_9279_x crossref_primary_10_1002_asia_201000817 crossref_primary_10_3390_molecules30010091 crossref_primary_10_3390_curroncol29080471 crossref_primary_10_1021_acssuschemeng_1c06522 crossref_primary_10_1021_op700288p crossref_primary_10_1080_14756366_2018_1465417 crossref_primary_10_1016_j_bmc_2006_08_040 crossref_primary_10_1021_jm3007257 crossref_primary_10_1517_13543776_2011_616283 crossref_primary_10_1016_j_bone_2015_07_016 crossref_primary_10_1517_13543780902832661 crossref_primary_10_1016_j_cbpa_2014_08_011 crossref_primary_10_1016_j_bone_2006_07_015 crossref_primary_10_1039_c2ra21302h crossref_primary_10_1021_acsomega_8b03258 crossref_primary_10_1007_s12018_011_9094_6 crossref_primary_10_1016_j_tet_2009_06_022 crossref_primary_10_3389_fimmu_2015_00252 crossref_primary_10_1038_nrrheum_2011_77 crossref_primary_10_1021_op100266s crossref_primary_10_1039_D1QO00070E crossref_primary_10_1021_jm9018756 crossref_primary_10_1517_13543771003604729 crossref_primary_10_1016_j_tetlet_2014_02_116 crossref_primary_10_1186_s12891_017_1625_y crossref_primary_10_1016_j_bmcl_2007_12_047 crossref_primary_10_3390_jcm2040176 crossref_primary_10_1016_j_pharmthera_2011_04_010 crossref_primary_10_1039_C7CC03307A crossref_primary_10_1074_jbc_M110_126706 crossref_primary_10_1016_j_bmcl_2011_06_045 crossref_primary_10_1016_j_chembiol_2007_03_010 crossref_primary_10_1039_C6RA14251F crossref_primary_10_1177_1759720X13490860 crossref_primary_10_1359_jbmr_091035 crossref_primary_10_1007_s11914_011_0085_9 crossref_primary_10_1016_j_isci_2022_104131 crossref_primary_10_1039_C8RA10338K crossref_primary_10_3762_bjoc_7_106 crossref_primary_10_1134_S1070428011030195 crossref_primary_10_3390_catal12101087 |
Cites_doi | 10.1021/jm020017n 10.2165/00003088-199223060-00005 10.1359/jbmr.1999.14.9.1562 10.1021/ac00238a024 10.1021/jo9824450 10.1359/jbmr.2001.16.10.1739 10.1021/bi00014a037 10.1002/jcc.540110405 10.1021/ja972204u 10.1016/S0040-4020(00)00965-0 10.1038/nsb0297-109 10.1021/ja01002a037 10.1016/S0169-409X(00)00129-0 10.1021/jm000942e 10.1021/ja00221a048 10.1016/S0065-7743(04)39007-X 10.1021/jm000481x 10.1016/j.tet.2004.05.124 |
ContentType | Journal Article |
Copyright | Copyright © 2006 American Chemical Society 2006 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2006 American Chemical Society – notice: 2006 INIST-CNRS |
DBID | BSCLL AAYXX CITATION 17B 1KM BLEPL DTL EGQ GAHYA IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1021/jm050915u |
DatabaseName | Istex CrossRef Web of Knowledge Index Chemicus Web of Science Core Collection Science Citation Index Expanded Web of Science Primary (SCIE, SSCI & AHCI) Web of Science - Science Citation Index Expanded - 2006 Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef Web of Science MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Web of Science MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 1KM name: Index Chemicus url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-4804 |
EndPage | 1612 |
ExternalDocumentID | 16509577 17595047 000236005400012 10_1021_jm050915u ark_67375_TPS_9WJTGJL8_D b65801388 |
Genre | Journal Article |
GroupedDBID | - .K2 4.4 53G 55A 5GY 5RE 5VS 7~N AABXI ABFLS ABMVS ABOCM ABPTK ABUCX ACGFS ACJ ACS AEESW AENEX AFEFF AFFNX ALMA_UNASSIGNED_HOLDINGS ANTXH AQSVZ BAANH CS3 DU5 EBS ED ED~ EJD F5P GJ GNL IH9 IHE JG JG~ K2 L7B LG6 NHB P2P ROL TN5 UI2 VF5 VG9 W1F WH7 X XFK YZZ ZY4 --- -~X .GJ AAHBH AAYOK ABJNI ABQRX ABTAH ACGFO ADHLV AGXLV AHGAQ BSCLL CUPRZ GGK IH2 XSW YQT AAYXX ABBLG ABLBI ACRPL ADNMO AEYZD AGQPQ ANPPW CITATION 17B 1KM BLEPL DTL GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED GROUPED_WOS_WEB_OF_SCIENCE .55 .HR 1KJ 1WB 3EH 3O- 6P2 6TJ 9M8 ABHMW ADXHL IQODW MVM OHT RNS UBC X7M ZE2 ZGI CGR CUY CVF ECM EIF NPM VXZ YIN 7X8 |
ID | FETCH-LOGICAL-a447t-d4706ef60692b8d4a6c58f2e04f0e58f966950b8b1c65e349d8b6982daa3e2783 |
IEDL.DBID | ACS |
ISICitedReferencesCount | 59 |
ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000236005400012 |
ISSN | 0022-2623 |
IngestDate | Mon Jul 21 10:03:11 EDT 2025 Wed Feb 19 01:42:19 EST 2025 Mon Jul 21 09:13:57 EDT 2025 Fri Aug 29 16:14:40 EDT 2025 Wed Aug 06 05:58:34 EDT 2025 Thu Apr 24 23:07:34 EDT 2025 Tue Jul 01 02:12:54 EDT 2025 Wed Oct 30 09:58:52 EDT 2024 Thu Aug 27 13:42:07 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | DESIGN POTENT ASSAY CRYSTAL-STRUCTURE BINDING CONFORMATIONS MOLECULES Intravenous administration Rat Cysteine endopeptidases Monkey Non peptide compound Clearance Pyridine derivatives Structure activity relation Primates Chemical synthesis Cathepsin K Sulfonamide Enzyme Rodentia Oral administration Enzyme inhibitor Resorption Bioavailability In vitro Peptidases Vertebrata Mammalia Animal Hydrolases Carboxamide Benzofuran derivatives Bone Pharmacokinetics |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
MergedId | FETCHMERGED-LOGICAL-a447t-d4706ef60692b8d4a6c58f2e04f0e58f966950b8b1c65e349d8b6982daa3e2783 |
Notes | istex:FC16672AD431F4665E82A71D84D51E5530A0082A ark:/67375/TPS-9WJTGJL8-D ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2378-7283 |
PMID | 16509577 |
PQID | 67711702 |
PQPubID | 23479 |
PageCount | 16 |
ParticipantIDs | proquest_miscellaneous_67711702 webofscience_primary_000236005400012 pubmed_primary_16509577 acs_journals_10_1021_jm050915u pascalfrancis_primary_17595047 istex_primary_ark_67375_TPS_9WJTGJL8_D crossref_primary_10_1021_jm050915u crossref_citationtrail_10_1021_jm050915u webofscience_primary_000236005400012CitationCount |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ANTXH ACS AEESW AFEFF .K2 ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2006-03-09 |
PublicationDateYYYYMMDD | 2006-03-09 |
PublicationDate_xml | – month: 03 year: 2006 text: 2006-03-09 day: 09 |
PublicationDecade | 2000 |
PublicationPlace | WASHINGTON |
PublicationPlace_xml | – name: WASHINGTON – name: Washington, DC – name: United States |
PublicationTitle | Journal of medicinal chemistry |
PublicationTitleAbbrev | J MED CHEM |
PublicationTitleAlternate | J. Med. Chem |
PublicationYear | 2006 |
Publisher | American Chemical Society Amer Chemical Soc |
Publisher_xml | – name: American Chemical Society – name: Amer Chemical Soc |
References | Thompson M. (jm050915ub00011/jm050915ub00011_1) 1982; 54 Yamashita D. S. (jm050915ub00002/jm050915ub00002_1) 1997; 119 Stroup G. B. (jm050915ub00001/jm050915ub00001_1) 2001; 16 Veber D. F. (jm050915ub00013/jm050915ub00013_1) 2002; 45 Ertl P. (jm050915ub00015/jm050915ub00015_1) 2000; 43 James I. E. (jm050915ub00010/jm050915ub00010_1) 1999; 14 Morrison J. F. (jm050915ub00017/jm050915ub00017_1) 1988; 61 Gabrielsson J. (jm050915ub00019/jm050915ub00019_1) 1997 Gula M. J. (jm050915ub00007/jm050915ub00007_1) 1988; 110 Brandt M. (jm050915ub00016/jm050915ub00016_1) 1989; 28 Marquis R. W. (jm050915ub00003/jm050915ub00003_1) 2001; 44 Pacifici G. M. (jm050915ub00020/jm050915ub00020_1) 1992; 23 Luzzio F. A (jm050915ub00004/jm050915ub00004_1) 2001; 57 Grubbs R. H. (jm050915ub00005/jm050915ub00005_1) 2004; 60 Hendrickson J. B. (jm050915ub00006/jm050915ub00006_1) 1967; 89 Lipinski C. A. (jm050915ub00014/jm050915ub00014_1) 2001; 46 Zhao B. (jm050915ub00009/jm050915ub00009_1) 1997; 4 Turk D. (jm050915ub00012/jm050915ub00012_1) 1995; 34 Mohamadi F. (jm050915ub00018/jm050915ub00018_1) 1990; 11 Nevins N. (jm050915ub00008/jm050915ub00008_1) 1999; 64 Stroup, GB (WOS:000171142000001) 2001; 16 TURK, D (WOS:A1995QT03200037) 1995; 34 PACIFICI, GM (WOS:A1992KA09300004) 1992; 23 James, IE (WOS:000082276000012) 1999; 14 Grubbs, RH (WOS:000223090800003) 2004; 60 Luzzio, FA (WOS:000166786700001) 2001; 57 FAVINI G (WOS:000236005400012.3) 1983; 93 Kansy, M (WOS:000072852600001) 1998; 41 Yamashita, DS (WOS:000085302300002) 2000; 6 MOHAMADI, F (WOS:A1990CZ22100004) 1990; 11 Veber, DF (WOS:000175957700030) 2002; 45 THOMPSON, M (WOS:A1982MW08100026) 1982; 54 Marquis, RW (WOS:000168443100009) 2001; 44 BRANDT, M (WOS:A1989R737300021) 1989; 28 HENDRICKSON, JB (WOS:A1967A393800036) 1967; 89 Marquis, RW (WOS:000228477500007) 2004; 39 GABRIELSSON J (WOS:000236005400012.4) 1997 Zhao, BG (WOS:A1997WF96100009) 1997; 4 Marquis, RW (WOS:000075892000003) 1998; 41 Snyder, JP (WOS:000085165200028) 2000; 122 MORRISON, JF (WOS:A1988N206500005) 1988; 61 GULA, MJ (WOS:A1988P073900047) 1988; 110 Nevins, N (WOS:000080681400035) 1999; 64 Ertl, P (WOS:000089725000014) 2000; 43 Lipinski, CA (WOS:000167611100002) 2001; 46 Yamashita, DS (WOS:A1997YG90100039) 1997; 119 |
References_xml | – volume: 45 start-page: 2623 year: 2002 ident: jm050915ub00013/jm050915ub00013_1 publication-title: J. Med. Chem. doi: 10.1021/jm020017n – volume: 23 start-page: 468 year: 1992 ident: jm050915ub00020/jm050915ub00020_1 publication-title: Clin. Pharmacokinet. doi: 10.2165/00003088-199223060-00005 – volume: 14 start-page: 1569 year: 1999 ident: jm050915ub00010/jm050915ub00010_1 publication-title: J. Bone Miner. Res. doi: 10.1359/jbmr.1999.14.9.1562 – volume: 54 start-page: 81 year: 1982 ident: jm050915ub00011/jm050915ub00011_1 publication-title: Anal. Chem. doi: 10.1021/ac00238a024 – volume: 61 start-page: 301 year: 1988 ident: jm050915ub00017/jm050915ub00017_1 publication-title: Adv. Enzymol. Relat. Areas Mol. Biol. – volume: 64 start-page: 3986 issue: 11 year: 1999 ident: jm050915ub00008/jm050915ub00008_1 publication-title: J. Org. Chem. doi: 10.1021/jo9824450 – volume: 16 start-page: 1746 issue: 10 year: 2001 ident: jm050915ub00001/jm050915ub00001_1 publication-title: J. Bone Miner. Res. doi: 10.1359/jbmr.2001.16.10.1739 – volume: 34 start-page: 4797 year: 1995 ident: jm050915ub00012/jm050915ub00012_1 publication-title: Biochemistry doi: 10.1021/bi00014a037 – volume: 11 start-page: 467 issue: 4 year: 1990 ident: jm050915ub00018/jm050915ub00018_1 publication-title: J. Comput. Chem. doi: 10.1002/jcc.540110405 – volume: 119 start-page: 11352 year: 1997 ident: jm050915ub00002/jm050915ub00002_1 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja972204u – volume: 57 start-page: 945 year: 2001 ident: jm050915ub00004/jm050915ub00004_1 publication-title: Tetrahedron doi: 10.1016/S0040-4020(00)00965-0 – volume: 4 start-page: 111 issue: 2 year: 1997 ident: jm050915ub00009/jm050915ub00009_1 publication-title: Nat. Struct. Biol. doi: 10.1038/nsb0297-109 – volume: 28 start-page: 148 year: 1989 ident: jm050915ub00016/jm050915ub00016_1 publication-title: Biochemistry – volume-title: Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications year: 1997 ident: jm050915ub00019/jm050915ub00019_1 – volume: 60 start-page: 7140 year: 2004 ident: jm050915ub00005/jm050915ub00005_1 publication-title: Tetrahedron – volume: 89 start-page: 7043 year: 1967 ident: jm050915ub00006/jm050915ub00006_1 publication-title: Am. Chem. Soc. doi: 10.1021/ja01002a037 – volume: 46 start-page: 26 year: 2001 ident: jm050915ub00014/jm050915ub00014_1 publication-title: Adv. Drug. Del. Rev. doi: 10.1016/S0169-409X(00)00129-0 – volume: 43 start-page: 3717 year: 2000 ident: jm050915ub00015/jm050915ub00015_1 publication-title: J. Med. Chem. doi: 10.1021/jm000942e – volume: 44 start-page: 1395 year: 2001 ident: jm050915ub00003/jm050915ub00003_1 publication-title: J. Med. Chem. – volume: 110 start-page: 4405 year: 1988 ident: jm050915ub00007/jm050915ub00007_1 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja00221a048 – volume: 119 start-page: 11351 year: 1997 ident: WOS:A1997YG90100039 article-title: Structure and design of potent and selective cathepsin K inhibitors publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY – volume: 43 start-page: 3714 year: 2000 ident: WOS:000089725000014 article-title: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties publication-title: JOURNAL OF MEDICINAL CHEMISTRY – volume: 93 start-page: 139 year: 1983 ident: WOS:000236005400012.3 publication-title: J MOL STRUCT – volume: 41 start-page: 3563 year: 1998 ident: WOS:000075892000003 article-title: Conformationally constrained 1,3-diamino ketones: A series of potent inhibitors of the cysteine protease cathepsin K publication-title: JOURNAL OF MEDICINAL CHEMISTRY – volume: 11 start-page: 440 year: 1990 ident: WOS:A1990CZ22100004 article-title: MACROMODEL - AN INTEGRATED SOFTWARE SYSTEM FOR MODELING ORGANIC AND BIOORGANIC MOLECULES USING MOLECULAR MECHANICS publication-title: JOURNAL OF COMPUTATIONAL CHEMISTRY – volume: 45 start-page: 2615 year: 2002 ident: WOS:000175957700030 article-title: Molecular properties that influence the oral bioavailability of drug candidates publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm020017n – volume: 23 start-page: 449 year: 1992 ident: WOS:A1992KA09300004 article-title: METHODS OF DETERMINING PLASMA AND TISSUE BINDING OF DRUGS - PHARMACOKINETIC CONSEQUENCES publication-title: CLINICAL PHARMACOKINETICS – volume: 61 start-page: 201 year: 1988 ident: WOS:A1988N206500005 article-title: THE BEHAVIOR AND SIGNIFICANCE OF SLOW-BINDING ENZYME-INHIBITORS publication-title: ADVANCES IN ENZYMOLOGY AND RELATED AREAS OF MOLECULAR BIOLOGY – volume: 28 start-page: 140 year: 1989 ident: WOS:A1989R737300021 article-title: 3-BETA-HYDROXY-DELTA-5-STEROID DEHYDROGENASE/3-KETO-DELTA-5-STEROID ISOMERASE FROM BOVINE ADRENALS - MECHANISM OF INHIBITION BY 3-OXO-4-AZA STEROIDS AND KINETIC MECHANISM OF THE DEHYDROGENASE publication-title: BIOCHEMISTRY – year: 1997 ident: WOS:000236005400012.4 publication-title: PHARMACOKINETIC PHAR – volume: 14 start-page: 1562 year: 1999 ident: WOS:000082276000012 article-title: Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents publication-title: JOURNAL OF BONE AND MINERAL RESEARCH – volume: 34 start-page: 4791 year: 1995 ident: WOS:A1995QT03200037 article-title: CRYSTAL-STRUCTURE OF CATHEPSIN-B INHIBITED WITH CA030 AT 2.0-ANGSTROM RESOLUTION - A BASIS FOR THE DESIGN OF SPECIFIC EPOXYSUCCINYL INHIBITORS publication-title: BIOCHEMISTRY – volume: 54 start-page: 76 year: 1982 ident: WOS:A1982MW08100026 article-title: STRUCTURE AND ELECTROCHEMICAL PROPERTIES OF MICRO-FILTRATION FILTER LIPID-MEMBRANE SYSTEMS publication-title: ANALYTICAL CHEMISTRY – volume: 6 start-page: 1 year: 2000 ident: WOS:000085302300002 article-title: Cathepsin K and the design of inhibitors of cathepsin K publication-title: CURRENT PHARMACEUTICAL DESIGN – volume: 41 start-page: 1007 year: 1998 ident: WOS:000072852600001 article-title: Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes publication-title: JOURNAL OF MEDICINAL CHEMISTRY – volume: 39 start-page: 79 year: 2004 ident: WOS:000228477500007 article-title: Inhibition of the cysteine protease cathepsin K (EC 3.4.22.38) publication-title: ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 39 doi: 10.1016/S0065-7743(04)39007-X – volume: 44 start-page: 1380 year: 2001 ident: WOS:000168443100009 article-title: Azepanone-based inhibitors of human and rat cathepsin K publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm000481x – volume: 16 start-page: 1739 year: 2001 ident: WOS:000171142000001 article-title: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate publication-title: JOURNAL OF BONE AND MINERAL RESEARCH – volume: 64 start-page: 3979 year: 1999 ident: WOS:000080681400035 article-title: A test of the single-conformation hypothesis in the analysis of NMR data for small polar molecules: A force field comparison publication-title: JOURNAL OF ORGANIC CHEMISTRY – volume: 57 start-page: 915 year: 2001 ident: WOS:000166786700001 article-title: The Henry reaction: recent examples publication-title: TETRAHEDRON – volume: 4 start-page: 109 year: 1997 ident: WOS:A1997WF96100009 article-title: Crystal structure of human osteoclast cathepsin K complex with E-64 publication-title: NATURE STRUCTURAL BIOLOGY – volume: 46 start-page: 3 year: 2001 ident: WOS:000167611100002 article-title: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (Reprinted from Advanced Drug Delivery Reviews, vol 23, pg 3-25, 1997) publication-title: ADVANCED DRUG DELIVERY REVIEWS – volume: 122 start-page: 724 year: 2000 ident: WOS:000085165200028 article-title: The conformations of taxol in chloroform publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY – volume: 89 start-page: 7036 year: 1967 ident: WOS:A1967A393800036 article-title: MOLECULAR GEOMETRY .V. EVALUATION OF FUNCTIONS AND CONFORMATIONS OF MEDIUM RINGS publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY – volume: 110 start-page: 4400 year: 1988 ident: WOS:A1988P073900047 article-title: EVALUATION OF 1,3-DIAXIAL STERIC HINDRANCE TO PROTON ABSTRACTION ALPHA TO CARBONYL GROUPS publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY – volume: 60 start-page: 7117 year: 2004 ident: WOS:000223090800003 article-title: Olefin metathesis publication-title: TETRAHEDRON doi: 10.1016/j.tet.2004.05.124 |
SSID | ssj0003123 |
Score | 2.105938 |
Snippet | The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based... The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-iiiethyl-substituted... |
Source | Web of Science |
SourceID | proquest pubmed pascalfrancis webofscience crossref istex acs |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1597 |
SubjectTerms | Animals Azepines - chemical synthesis Azepines - chemistry Azepines - pharmacology Biological and medical sciences Biological Availability Blood Proteins - metabolism Bone Density Conservation Agents - chemical synthesis Bone Density Conservation Agents - chemistry Bone Density Conservation Agents - pharmacology Bones, joints and connective tissue. Antiinflammatory agents Cathepsin K Cathepsins - antagonists & inhibitors Cathepsins - chemistry Cell Line Cell Membrane Permeability Chemistry, Medicinal Crystallography, X-Ray Haplorhini Humans Life Sciences & Biomedicine Medical sciences Molecular Conformation Pharmacology & Pharmacy Pharmacology. Drug treatments Protein Binding Rats Science & Technology Stereoisomerism Structure-Activity Relationship Sulfones - chemical synthesis Sulfones - chemistry Sulfones - pharmacology |
Title | Structure Activity Relationships of 5-, 6-, and 7-Methyl-Substituted Azepan-3-one Cathepsin K Inhibitors |
URI | http://dx.doi.org/10.1021/jm050915u https://api.istex.fr/ark:/67375/TPS-9WJTGJL8-D/fulltext.pdf http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000236005400012 https://www.ncbi.nlm.nih.gov/pubmed/16509577 https://www.proquest.com/docview/67711702 |
Volume | 49 |
WOS | 000236005400012 |
WOSCitedRecordID | wos000236005400012 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfG9gAvAwaM8DEsmCoe6pE4tmM_Vh1jFIYqtRN7i-zEUbuNtFpaie2v55yvbqJ8PESKlLMT3519d_H5dwjtSyWo8WVKGMsgQBG-JcpQTSCYEJzLLKEldufJN3F8ygZn_GwDvfvDDj4NPpz_cBAlAV_eQ1tUyMhFWL3-qF1uw4CGDSQ4BWPewAfdbupMT1LcMT1bjos_XSqkLoAbWVXGYp2fudYklebn6CE6bA7xVFknFwfLhTlIbn7HdPzbyB6h7dr9xL1KXx6jDZvvoPv9purbDuoMKyzr6y4er45mFV3cwcMVyvX1EzQZlcizyyuLe0lVggK3mXWT6bzAswxz0sUCLp2nOCInFrTikri1qkpQSHHvBsxhTkIyyy0uTyPOi2mOv-DP-WRqpq4U0FN0evRx3D8mddkGohmLFiRlkS9sBpGRokamTIsEhE6tzzLfwh0EWIr7RpogEdyGTKXSCCVpqnVoXeGPZ2gzh7c-R1hLppIsVJpnmlnFjAHvzgZCS8FsIgMP7YFc43raFXG5o04homk466H3jcjjpAY9d7U3LteRvm1J5xXSxzqiTqk3LYW-unCpcRGPx8NRrL4Pxp8GX2V8CF92R7FWXUYcRs8iD71pNC0GEbttGp3b2bKA7iJXDoh6aLdSwFVbB3fII2i7f1sj2-clepEovXDnxnoo-B-yfs0XB4KwePEvjr5ED6q_UCHx1Su0CbpmX4NftjB75bz8BXUWLcU |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swELc2eGAv-2BfZRtYE6r2UEPi2E78WHVjpbSoUovGW2QnjtoBaUVaafDX7-wkLUyVxkOkSDk79uWX3F18_h1Ch5EUVHtRShjLIEARniFSU0UgmBCcR1lCHXfn4Fx0L1jvkl9WNDl2LwwMooCeCreIv2YX8I9_31imEp8vn6NtcEKoDbTandHqqxv4NKiZwSnY9JpF6GFTa4GS4pEF2rbK_GMzIlUBSsnKahab3M2NlslZoZNXZTkjN36XfHJ1tFzoo-T-H2rHp03wNXpZOaO4XaLnDXpm8l2006lrwO2i5rBktr5r4fF6o1bRwk08XHNe371Fk5HjoV3eGtxOyoIUeJVnN5nOCzzLMCctLOBQeYpDMjCAkWtiv1xlukKK2_dgHHMSkFlusNubOC-mOT7Dp_lkqqe2MNA7dHHyY9zpkqqIA1GMhQuSstATJoM4SVIdpUyJBCBAjccyz8AZhFuSezrSfiK4CZhMIy1kRFOlAmPLgLxHWznc9SPCKmIyyQKpeKaYkUxr8PWML1QkmEkiv4H2QbFx9RIWsVtfpxDf1JptoG_1k4-TigLdVuK43iT6dSU6L3k_Ngk1HXxWEur2yibKhTweD0ex_NUb_-z1o_g7jOwRvtZdhhxmz8IGOqgBF8Mjtos2KjezZQHdhbY4EG2gDyUO120t-SEPoe3hQ2CurjsuI-F8cuvUNpD_FLFOpRdLibDY-59GD9BOdzzox_3T87NP6EX5fyognvyMtgB35gt4bAu9717Vv7wgNiY |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swELc2kLa9jI2NLfsAa0LVHmqWD8exH6tCB-VjlVo03iI7cdQOllaklQZ_PWfno4AqjYdIkXJx7MvPubv4_DuEdrlgvnJ5SijNIEBhriZC-ZJAMMHCkGeJb7k7T8_Y4TntX4QXVaBo9sJAJwpoqbCL-GZWz9KsYhjwfvz5a9hKvHDxHK2b5ToTbHW6w-bLG3h-ULOD-2DXayah-7caK5QUD6zQulHoP5MVKQtQTFZWtFjlcq60TtYS9TbQr2YMNgHlcm8xV3vJ7SN6x6cP8g16XTmluFOi6C16pvNN9LJb14LbRK1ByXB908aj5Yatoo1beLDkvr55h8ZDy0e7uNa4k5SFKXCTbzeezAo8zXBI2pjBIfMUR-RUA1auiPmClWkLKe7cgpHMSUCmucZ2j-KsmOT4GB_l44mamAJB79F572DUPSRVMQciKY3mJKWRy3QG8ZLwFU-pZAlAwdcuzVwNZxB2idBVXHkJC3VARcoVE9xPpQy0KQeyhdZyeOpHhCWnIskCIcNMUi2oUuDzaY9JzqhOuOegbVBuXE3GIrbr7D7EObVmHfS9fvtxUlGhm4ocV6tEvzWis5L_Y5VQy0KokZDXlyZhLgrj0WAYi9_90c_-CY_3oWcPMLZsMgph9DRy0E4NuhhesVm8kbmeLgpoLjJFgnwHfSixuLzXkCDCZHDQ7n1wNtctpxGzvrlxbh3kPUWsW-nFUCPMP_1PozvoxWC_F58cnR1_Rq_K31QBccUXtAaw01_BcZurbTtb7wDGTDip |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure+Activity+Relationships+of+5-%2C+6-%2C+and+7-Methyl-Substituted+Azepan-3-one+Cathepsin+K+Inhibitors&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Yamashita%2C+Dennis+S&rft.au=Marquis%2C+Robert+W&rft.au=Xie%2C+Ren&rft.au=Nidamarthy%2C+Sirishkumar+D&rft.date=2006-03-09&rft.pub=American+Chemical+Society&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=49&rft.issue=5&rft.spage=1597&rft.epage=1612&rft_id=info:doi/10.1021%2Fjm050915u&rft.externalDocID=b65801388 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |